NetWorth
LeaderPortfolio
Halbert
D
Rank #1799
UNITED STATES•Healthcare•Biotech

David Dean Halbert

Net Worth
$2.279B
+1.1% (24h)
David Dean Halbert is a highly successful entrepreneur, currently serving as the Chairman, Founder, and CEO of Caris Life Sciences. With over 40 years of experience in the healthcare, finance, and energy sectors, Halbert has established himself as a leader in the industry. His career began with the founding of AdvancePCS in 1987, a pharmacy benefits management company that he later sold for $7.5 billion. In 2008, he acquired Molecular Profiling Institute, which he transformed and renamed Caris Life Sciences. Under his leadership, Caris Life Sciences has become a leading precision medicine company focused on revolutionizing cancer care through molecular profiling and AI. Halbert's dedication to personalized medicine, driven by a personal experience with cancer, has led to significant advancements in the field. His net worth is estimated at $2.7 billion, and he is recognized as one of the most successful entrepreneurs in the United States.

How to read David Dean Halbert's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For David Dean Halbert, we anchor the narrative to Biotech and Biotech, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $2.279B alongside global rank #1799, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (UNITED STATES) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

David Dean Halbert was born in Abilene, Texas, in 1956. He graduated with a Bachelor of Business Administration from Abilene Christian University in 1978. Halbert's upbringing in a Christian household and his education played a significant role in shaping his personal and professional life, instilling in him a sense of stewardship and a desire to use his resources effectively.

Rise to Success

Halbert's entrepreneurial journey began in 1987 with the founding of AdvancePCS, a pharmacy benefits management company. Under his leadership as Chairman and CEO, AdvancePCS grew into a publicly traded, Fortune 250 corporation with over $15 billion in annual revenue. He took the company public and later sold it to Caremark in 2004 for $7.5 billion. Halbert's subsequent venture, Caris Life Sciences, marked a significant shift towards precision medicine. He acquired Molecular Profiling Institute in 2008 and transformed it into Caris Life Sciences, a leader in molecular science and AI-driven diagnostics. Caris Life Sciences went public in June 2025.

Key Business Strategies

Halbert's business strategy has been marked by a focus on innovation and strategic acquisitions. At AdvancePCS, he supplemented internal development with 11 successful strategic acquisitions. Caris Life Sciences has become a leader in the field of precision medicine through the use of gene sequencing, AI, and machine learning for early disease detection. Halbert has also demonstrated a keen ability to identify and capitalize on emerging trends in the healthcare industry.

Philanthropy

Halbert and his family created and solely support the Caris Foundation™, a non-profit organization aiding impoverished people, particularly in Africa and Haiti. The foundation supports basic needs and has been involved in significant investments to bolster healthcare systems. Halbert's commitment to philanthropy is also evident in his contributions to educational institutions, including Abilene Christian University, where he helped fund the Halbert-Walling Research Center and Wildcat Stadium.

Career Timeline

2025

Caris Life Sciences IPO

Caris Life Sciences went public on the Nasdaq.

2008

Acquired Molecular Profiling Institute

Acquired Molecular Profiling Institute, later renamed Caris Life Sciences.

2004

Sold AdvancePCS

Sold AdvancePCS to Caremark for $7.5 billion.

1987

Founded AdvancePCS

Founded pharmacy benefits management company.

Philanthropic Impact

Healthcare/Education$15M

Caris Foundation

Provided funding to build the Halbert-Walling Research Center and Wildcat Stadium

HealthcareUndisclosed

Project Santé

Supported initiatives to bolster Haiti's health system and expand essential healthcare.

Key Business Ventures & Holdings

CompanyStakeValue
Caris Life Sciences44.00%—

Net Worth History

In-Depth Analysis

Early Life and Education

David Dean Halbert was born in Abilene, Texas, in 1956. He graduated with a Bachelor of Business Administration from Abilene Christian University in 1978. Halbert's upbringing in a Christian household and his education played a significant role in shaping his personal and professional life, instilling in him a sense of stewardship and a desire to use his resources effectively.

Rise to Success

Halbert's entrepreneurial journey began in 1987 with the founding of AdvancePCS, a pharmacy benefits management company. Under his leadership as Chairman and CEO, AdvancePCS grew into a publicly traded, Fortune 250 corporation with over $15 billion in annual revenue. He took the company public and later sold it to Caremark in 2004 for $7.5 billion. Halbert's subsequent venture, Caris Life Sciences, marked a significant shift towards precision medicine. He acquired Molecular Profiling Institute in 2008 and transformed it into Caris Life Sciences, a leader in molecular science and AI-driven diagnostics. Caris Life Sciences went public in June 2025.

Key Business Strategies

Halbert's business strategy has been marked by a focus on innovation and strategic acquisitions. At AdvancePCS, he supplemented internal development with 11 successful strategic acquisitions. Caris Life Sciences has become a leader in the field of precision medicine through the use of gene sequencing, AI, and machine learning for early disease detection. Halbert has also demonstrated a keen ability to identify and capitalize on emerging trends in the healthcare industry.

Philanthropy

Halbert and his family created and solely support the Caris Foundation™, a non-profit organization aiding impoverished people, particularly in Africa and Haiti. The foundation supports basic needs and has been involved in significant investments to bolster healthcare systems. Halbert's commitment to philanthropy is also evident in his contributions to educational institutions, including Abilene Christian University, where he helped fund the Halbert-Walling Research Center and Wildcat Stadium.

Data Sources & Methodology

Figures for David Dean Halbert are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom